NodThera Limited

NodThera Limited is a biotechnology firm dedicated to developing novel therapies targeting chronic inflammatory diseases through its proprietary NLRP3 inflammasome inhibitors, with a focus on improving patient outcomes across various conditions. NodThera Limited is engaged in the biopharmaceutical sector, working on therapies targeting chronic inflammation. The company was founded in 2016 and is headquartered in Cambridge, UK. It has successfully completed three funding rounds, with the latest being a Series B round on June 2, 2020, where it raised GBP 32.

40 million, led by Novo Holdings, and has a current valuation of GBP 109. 075 million. The CEO, Alan Watt, has a background in biotechnology and has been instrumental in guiding the company’s strategic direction. NodThera focuses on developing innovative therapies aimed at chronic inflammatory diseases by utilizing its research on NLRP3 inflammasome inhibitors.

The company's pipeline includes several assets at various stages of development, targeting conditions such as obesity and neurodegenerative diseases. Its customer base primarily includes healthcare providers and research institutions in North America and Europe, facilitating access to advanced treatments for patients. In 2021, NodThera reported a revenue of GBP 0. The company's business model revolves around partnerships and collaborations with pharmaceutical firms, which include milestone payments and royalties on successful product sales, but its EBITDA for 2023 was GBP -29,038,663.

1. NodThera plans to leverage its Series B funding of GBP 32. 40 million to support the development of new therapies targeting chronic inflammatory diseases. The company aims to expand its market presence in North America and Europe while continuing to advance its clinical pipeline.

The Series B funding positions NodThera with a post-money valuation of GBP 109 million, allowing it to enhance its research capabilities and expedite the commercialization of its NLRP3-targeting therapies.